CSF levels of DJ-1 and tau distinguish MSA patients from PD patients and controls

Area of Science:

• Neuroscience
• Biochemistry
• Clinical Diagnostics

Background:

• Distinguishing Parkinson's disease (PD) from multiple system atrophy (MSA) is clinically challenging, especially in early stages.
• Accurate differential diagnosis is crucial for appropriate therapeutic management.
• The role of DJ-1 protein in MSA pathology is largely unknown, despite its implication in PD.

Purpose of the Study:

• To investigate the diagnostic utility of cerebrospinal fluid (CSF) DJ-1 and tau proteins in differentiating PD from MSA.
• To assess the combined potential of DJ-1 and tau as biomarkers for differential diagnosis.

Main Methods:

• Quantification of DJ-1 and total tau protein levels in CSF samples from 43 PD patients, 23 MSA patients, and 30 controls.
• Utilized a 3-year prospective study design with up to 9 years of follow-up for accurate clinical diagnosis.
• Statistical analysis including Area Under the Curve (AUC) to evaluate diagnostic performance.

Main Results:

• CSF DJ-1 levels alone distinguished MSA from PD with 78% sensitivity and 78% specificity (AUC = 0.84).
• The combination of DJ-1 and tau proteins improved discrimination, achieving 82% sensitivity and 81% specificity for identifying MSA versus PD (AUC = 0.92).

Conclusions:

• CSF DJ-1 protein shows potential as a biomarker for differentiating MSA from PD.
• Combining DJ-1 and total tau levels offers enhanced accuracy for the differential diagnosis of MSA and PD.